浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 证券简称：莎普爱思 证券代码：603168 浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 二〇二三年八月 1 浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 声 明 本公司及全体董事、监事保证本激励计划及其摘要不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示 一、《浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励 计划》（以下简称"本激励计划"）由浙江莎普爱思药业股份有限公司（以下简 称"莎普爱思"、"公司"或"本公司"）依据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司股权激励管理办法》和其他有关法律、行政法 规、规范性文件，以及《公司章程》等有关规定制订。 二、本激励计划包括股票期权激励计划和限制性股票激励计划两部分。股票 来源为公司向激励对象定向发行的本公司人民币 A 股普通股股票。 三、本激励计划包括股票期权激励计划和限制性股票激励计划两部分。本激 励计划拟授予激励对象的权益总计为 856.50 ...

北京市金杜律师事务所上海分所关于 浙江莎普爱思药业股份有限公司 2023 年第一次临时股东大会 之法律意见书 致：浙江莎普爱思药业股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受浙江莎普爱思药业股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委 员会《上市公司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）等 中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国 香港特别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政 法规、规章和规范性文件和现行有效的《浙江莎普爱思药业股份有限公司章程》（以 下简称《公司章程》）有关规定，指派律师出席并见证公司于 2023 年 8 月 9 日召 开的 2023 年第一次临时股东大会（以下简称本次股东大会），并就本次股东大会 相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司第五届董事会第十三次会议审议批准的《公司章程》； 2. 公司 2023 年 7 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临2023-037 浙江莎普爱思药业股份有限公司 关于召开2022年度暨2023年第一季度 业绩说明会的公告 会议召开时间：2023 年 5 月 12 日（星期五）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 （www.ir-online.cn）举办浙江莎普爱思药业股份有限公司 2022 年度及 2023 年 第一季度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 二、 说明会召开的时间、地点和方式 会议召开时间：2023 年 5 月 12 日（星期五）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 5 月 12 日 前 访 问 网 址 https://eseb.cn/148l200TbTW 或使用微信扫描下方小程序码进行会前提问， ...

Financial Performance - In 2022, the company achieved a net profit of CNY 16,906,297.90, with a distributable net profit of CNY 349,139,174.93 after accounting for reserves[6]. - The proposed cash dividend is CNY 0.37 per 10 shares, totaling CNY 13,783,018.19, which represents 90.58% of the distributable net profit for the year[6]. - The company achieved operating revenue of CNY 549.54 million in 2022, a decrease of 12.74% compared to the previous year[30]. - The net profit attributable to shareholders was CNY 45.94 million, representing a year-on-year increase of 28.83%[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20.18 million, down 35.05% year-on-year, primarily due to lower sales of eye drops and increased raw material costs for certain products[30]. - Basic and diluted earnings per share were CNY 0.14, an increase of 27.27% from the previous year[29]. - The company's total assets reached CNY 1.96 billion at the end of 2022, a 23.49% increase from the previous year[28]. - The weighted average return on net assets was 3.22%, an increase of 0.54 percentage points compared to the previous year[29]. - The company reported a net cash flow from operating activities of CNY 115.72 million, up 14.82% year-on-year[28]. Dividend and Share Capital - The total share capital as of December 31, 2022, was 372,514,005 shares[6]. - The company did not issue bonus shares or increase capital reserves in 2022[6]. - The company plans to maintain the total distribution amount unchanged even if the total share capital changes before the dividend distribution date[6]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - There were no non-operational fund occupations by controlling shareholders or related parties[9]. - The company has established a robust corporate governance framework, ensuring compliance with relevant laws and protecting shareholder interests[153]. - The company’s information disclosure practices are aligned with regulatory requirements, ensuring transparency and accuracy in reporting[154]. Risks and Challenges - The company has outlined potential risks in its future development strategy, which investors should be aware of[11]. - The company faced challenges including lower-than-expected sales of eye drop products and a decline in sales of certain injections due to centralized procurement policies[30]. - The gross profit margin for certain products decreased due to rising raw material prices, impacting overall profitability[30]. - The implementation of centralized drug procurement policies is expected to impact sales of non-procurement products, although the direct impact on the company is currently minimal[94]. - The company faces industry policy risks due to new regulations in the pharmaceutical sector, which could adversely affect future operating performance if products do not comply[144]. Research and Development - Research and development expenses amounted to RMB 59.61 million, representing 10.85% of operating revenue[40]. - The company emphasizes R&D, collaborating with institutions like China Pharmaceutical University and Shanghai Jiao Tong University to strengthen its drug development capabilities[55]. - The company is focusing on ophthalmic drugs as its main R&D direction, developing proprietary pharmaceutical products[106]. - The company has made progress in new drug development, including obtaining a national Class 2 new drug certificate for the moxifloxacin eye drops[107]. - The company is actively pursuing new product development and expanding its patent portfolio to enhance its market position[107]. Market and Sales Strategy - The company has established a strong marketing network covering most provinces and cities in China, enhancing its market responsiveness[55]. - The company is actively advancing the consistency evaluation of Benzalkonium Chloride Eye Drops and has received approval for new product applications[41]. - The company plans to enhance its cost control capabilities and improve product competitiveness in response to regulatory changes[95]. - The company aims to enhance its marketing reform and expand new sales channels in the ophthalmic drug sector, while increasing R&D investment to optimize the ophthalmic product structure[137]. Social Responsibility and Community Engagement - The company actively engaged in social responsibility, donating 200,000 RMB and medical supplies during the pandemic, and providing free delivery of medications to residents[45]. - The company’s initiatives in public welfare included a large-scale charity event in Liangshan Yi Autonomous Prefecture, Sichuan Province, aimed at improving local healthcare conditions[46]. Employee and Management Structure - The company has a total of 1,241 employees, with 502 in the parent company and 739 in major subsidiaries[185]. - The employee composition includes 260 production staff, 277 sales personnel, 450 technical staff, 32 financial staff, and 222 administrative staff[185]. - The company has implemented a performance-based compensation system that links salaries directly to job performance and position[186]. Future Outlook and Strategic Plans - The company plans to strengthen the integration of pharmaceuticals and medical services, leveraging opportunities in the golden phase of pharmaceutical development in 2023[46]. - The company aims to improve operational efficiency by 10% through the implementation of advanced technologies in production processes[163]. - Future outlook includes a commitment to invest in research and development for innovative medical solutions, aiming for a 15% increase in R&D budget[163]. - The company plans to explore market expansion opportunities in Southeast Asia, targeting a 20% growth in international sales by 2024[163].

Financial Performance - The company's operating revenue for Q1 2023 was ¥162,202,066.07, representing an increase of 8.59% compared to the same period last year[5]. - The net profit attributable to shareholders decreased by 18.54% to ¥22,525,376.46[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 104.03% to ¥24,301,318.63[5]. - Basic and diluted earnings per share were both ¥0.06, down by 32.81% year-on-year[5][9]. - Net profit for Q1 2023 was ¥22,376,182.97, down 19.1% from ¥27,651,872.01 in Q1 2022[31]. - Operating profit for Q1 2023 decreased to ¥31,393,451.39 from ¥36,000,436.05 in Q1 2022, reflecting a decline of 12.5%[30]. - Research and development expenses decreased significantly to ¥10,201,993.58, a reduction of 50.7% compared to ¥20,623,127.13 in Q1 2022[30]. - The company's net profit for the first quarter of 2023 is yet to be disclosed, but the financial report indicates ongoing investments in new projects and partnerships[29]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥7,024,659.27, a decrease of 122.98% compared to the previous year[5][9]. - Cash flow from operating activities turned negative at -¥7,024,659.27 in Q1 2023, compared to a positive ¥30,565,574.33 in Q1 2022[33]. - Cash and cash equivalents decreased to CNY 440,240,971.36 from CNY 525,059,148.89, reflecting a decline of approximately 16.2%[25]. - Cash and cash equivalents at the end of Q1 2023 were ¥440,240,971.36, down from ¥258,587,877.03 at the end of Q1 2022[34]. - Total assets at the end of the reporting period were ¥2,000,665,004.28, an increase of 2.20% from the end of the previous year[6]. - Total current assets amounted to ¥727,804,786.34 as of Q1 2023[37]. - The company's current assets decreased to CNY 648,181,628.65 from CNY 727,804,786.34, representing a decline of approximately 10.9%[25]. - Total non-current assets reached ¥1,229,873,493.93, resulting in total assets of ¥1,957,678,280.27[38]. Equity and Liabilities - Shareholders' equity attributable to the parent company was ¥1,729,209,109.40, up by 1.32% from the previous year[6]. - The total equity attributable to shareholders rose to CNY 1,729,209,109.40 from CNY 1,706,683,732.94, an increase of approximately 1.3%[27]. - The total liabilities of the company rose to CNY 261,604,227.24 from CNY 240,993,686.20, indicating an increase of about 8.3%[27]. - Total current liabilities were reported at ¥205,816,952.14, while total liabilities amounted to ¥240,993,686.20[38]. - The company's total liabilities increased by approximately 2.5% from the previous period[38]. Investments and Acquisitions - The company completed the acquisition of 100% equity of Qingdao Shikang for RMB 66.5 million, enhancing its competitiveness in the ophthalmology market[17]. - The company applied for a merger loan of RMB 29 million from Zhejiang Pinghu Rural Commercial Bank to optimize its financing structure for the acquisition of Qingdao Shikang[18]. - The company has invested CNY 60 million in Shenzhen Jiusongtangyuan Investment Center, representing a 6% stake in the total capital[20]. - An additional investment of CNY 10 million was made in Hangzhou Suyin Linzhuo Equity Investment Partnership, accounting for a 10% stake[22]. Legal Matters - The company is involved in a lawsuit regarding equity transfer disputes, with the court freezing 51% and 49% equity stakes held by the defendants in Jilin Hongjing Pharmaceutical Co., Ltd.[16]. - The company signed a contract for the sale of 100% equity of Qiangshen Pharmaceutical, with an outstanding payment of RMB 40.18 million and overdue penalty of RMB 10.39 million due from Yue's Pharmaceutical[14]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[32]. - The company is actively advancing the consistency evaluation of Benzalkonium Chloride Eye Drops (Shapu Aisi) as per the requirements of the National Medical Products Administration and Zhejiang Provincial Medical Products Administration[13].

2022 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 证券代码：603168 证券简称：莎普爱思 浙江莎普爱思药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人鄢标、主管会计工作负责人林秀松及会计机构负责人（会计主管人员））林秀松 保证季度报告中财务信息的真实、准确、完整。 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 134,321,587.73 | -14.10 | 414,414,612.05 ...

Financial Performance - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders for the same period was RMB 300 million, up 10% compared to the previous year[14]. - The company’s gross margin improved to 60%, an increase of 5 percentage points from the previous year[14]. - The company achieved operating revenue of CNY 280.09 million, a decrease of 11.57% compared to the same period last year[22]. - Net profit attributable to shareholders increased by 32.19% to CNY 35.63 million, primarily due to the disposal gain from the transfer of 100% equity in Qiangshen Pharmaceutical[23]. - Basic and diluted earnings per share rose by 37.5% to CNY 0.11[21]. - Net profit after deducting non-recurring gains and losses was CNY 18.79 million, down 25.74% year-on-year[22]. - The weighted average return on net assets increased by 0.56 percentage points to 2.60%[21]. - The net cash flow from operating activities decreased by 64.14% to CNY 32.66 million[22]. - Total assets decreased by 2.80% to CNY 1.54 billion compared to the end of the previous year[22]. - The company’s net assets attributable to shareholders increased by 2.63% to CNY 1.39 billion[22]. Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on innovative drug formulations[14]. - Research and development expenses amounted to 30.12 million yuan, a decrease of 18.44%, representing 10.75% of total revenue[35]. - The company is actively advancing the consistency evaluation of its main product, Benda Lysine Eye Drops, with nine research units having completed participant enrollment[36]. - The company has formed partnerships with several universities and research institutions to strengthen its R&D capabilities[32]. - Zhejiang Shapuaisi is investing CNY 100 million in R&D for new technologies, focusing on innovative drug delivery systems[87]. Market Expansion and Product Launches - The company plans to launch two new products in the second half of 2022, targeting a market expansion of 25% in the ophthalmic drug segment[14]. - User data indicated that the number of active customers increased by 20% to 1.5 million in the first half of 2022[14]. - The company plans to launch three new products in the next quarter, aiming to capture a larger market share in the pharmaceutical sector[87]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 25% increase in international sales by the end of 2023[87]. Strategic Focus and Growth Plans - The company aims for a revenue growth target of 20% for the full year 2022, driven by new product launches and market expansion strategies[14]. - The company has no plans for significant mergers or acquisitions in the near term, focusing instead on organic growth[14]. - The company is focusing on the dual-driven strategy of "pharmaceuticals + medical services" to adapt to industry changes and enhance competitiveness[26]. - The company has completed a strategic acquisition of a local competitor, which is expected to enhance its market position and increase revenue by 10% annually[87]. Risk Factors and Challenges - Risk factors related to market competition and regulatory changes have been detailed in the management discussion section of the report[14]. - The company faces risks from industry policy changes, which could adversely affect future operating performance[52]. - The company is exposed to market risks in the pharmaceutical manufacturing industry, potentially leading to a decline in sales volume[53]. - The company acknowledges risks related to medical accidents, including surgical errors and misdiagnoses, which could adversely affect its operational performance and market reputation[59]. - Natural disasters and public health emergencies pose risks to the company's operations, necessitating effective response strategies to mitigate impacts on business and financial performance[62]. - The ongoing COVID-19 pandemic has led to a decline in outpatient and inpatient volumes, resulting in decreased medical service revenue[63]. Environmental and Social Responsibility - The company emphasized its commitment to social responsibility, actively participating in pandemic relief efforts and supporting local communities[39]. - The company is listed as a key pollutant discharge unit in Jiaxing City for 2022, with a total wastewater discharge of 32,253 tons[75]. - The company has established a comprehensive wastewater treatment station that employs a secondary aerobic biochemical treatment process[77]. - The company donated a batch of medicines to support the treatment of respiratory diseases in Moxi County, Sichuan, as part of its social responsibility efforts[82]. Financial Commitments and Shareholder Relations - The company has set a performance guidance for the full year 2022, projecting a revenue target of CNY 2.5 billion, which would represent a growth of 18% year-on-year[87]. - The company has proposed no profit distribution or capital reserve fund transfer for the half-year period, with no dividends or stock bonuses planned[72]. - The company has committed to compensating investors for losses due to false statements or omissions in the prospectus, ensuring protection of their legal rights[84]. - The company will actively take legal measures to fulfill all commitments made during the issuance and listing process, accepting supervision from regulatory authorities and the public[84]. - The company has established a compensation mechanism for performance commitments, where if the actual cumulative net profit falls below 90% of the promised amount, compensation will be paid based on the shortfall[89]. Financial Reporting and Accounting Practices - The company adheres to the enterprise accounting standards, ensuring the financial statements reflect a true and complete picture of its financial status[147]. - The financial statements are prepared based on the principle of continuous operation, indicating stability in operations[144]. - The company recognizes revenue based on the progress of performance obligations during a specific period[199]. - The company employs a three-stage model to measure expected credit losses for financial instruments, assessing credit risk based on common risk characteristics[162]. - The company recognizes short-term employee benefits as liabilities in the period services are provided, impacting current profits or related asset costs[192].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 149,368,784.48, representing a decrease of 2.48% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 27,651,872.01, an increase of 163.64% year-on-year[4]. - Basic and diluted earnings per share were both CNY 0.09, reflecting a 200% increase year-on-year[4]. - The company's total revenue for Q1 2022 was RMB 149.37 million, down 2.6% from RMB 153.16 million in Q1 2021[18]. - The company reported a net profit of RMB 35.76 million for Q1 2022, significantly up from RMB 17.44 million in Q1 2021, representing a growth of 104.5%[18]. - Net profit for Q1 2022 reached CNY 27,651,872.01, a significant increase of 164.5% compared to CNY 10,488,392.31 in Q1 2021[21]. - Total revenue from sales in Q1 2022 was CNY 169,739,076.41, compared to CNY 160,405,215.88 in Q1 2021, indicating a year-on-year increase of 5.5%[24]. - Gross profit for Q1 2022 was CNY 79,720,903.54, with a gross margin of approximately 72.8%[31]. - Net profit for Q1 2022 was CNY 11,977,096.42, down 18.8% from CNY 14,729,764.42 in Q1 2021[31]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 30,565,574.33, up by 144.92% compared to the previous year[4]. - Operating cash flow for Q1 2022 was CNY 30,565,574.33, up from CNY 12,479,810.76 in Q1 2021, representing a growth of 144.5%[24]. - The company reported a net cash increase of CNY 120,064,081.63 in Q1 2022, compared to CNY 112,622,702.82 in Q1 2021[25]. - Cash and cash equivalents increased by 86.67%, primarily due to the maturity of financial products[6]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 258,587,877.03, an increase from CNY 219,403,276.00 at the end of Q1 2021[25]. - The company's cash and cash equivalents rose to RMB 258.59 million as of March 31, 2022, compared to RMB 138.52 million at the end of 2021, reflecting improved liquidity[14]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 221,162,932.20, an increase from CNY 213,452,718.27 at the end of Q1 2021[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,540,916,953.81, a decrease of 2.80% from the end of the previous year[4]. - As of March 31, 2022, the company's total assets amounted to RMB 1.54 billion, a decrease from RMB 1.59 billion at the end of 2021[15]. - The company's total current assets as of March 31, 2022, were CNY 424,319,247.74, down from CNY 544,530,868.85 at the end of 2021[28]. - The total liabilities decreased to RMB 160.80 million as of March 31, 2022, from RMB 232.89 million at the end of 2021, indicating a reduction in financial obligations[16]. - The company's equity attributable to shareholders increased to RMB 1.38 billion as of March 31, 2022, compared to RMB 1.35 billion at the end of 2021, showing a positive trend in shareholder value[16]. - Total liabilities decreased to CNY 128,116,275.65 in Q1 2022 from CNY 190,974,766.88 in Q1 2021[30]. - The total assets as of Q1 2022 were CNY 1,527,308,479.73, down from CNY 1,578,189,874.54 in Q1 2021[30]. Investments and Equity - The company reported non-recurring gains and losses totaling CNY 15,741,337.45 for the period[5]. - The company completed the transfer of 100% equity of Qiangshen Pharmaceutical, receiving an initial payment of RMB 41.82 million and settling debts of RMB 88.06 million[12]. - The company has not yet received the remaining equity payment of RMB 40.18 million and a penalty of RMB 10.39 million from the buyer of Qiangshen Pharmaceutical[12]. - Long-term equity investments increased to CNY 639,515,379.16 as of March 31, 2022, compared to CNY 590,000,000.00 at the end of 2021[28]. Research and Development - Research and development expenses increased to RMB 20.62 million in Q1 2022, up from RMB 11.64 million in Q1 2021, indicating a focus on innovation[18]. - Research and development expenses increased to CNY 20,623,127.13 in Q1 2022, up from CNY 11,617,548.86 in Q1 2021, reflecting a focus on innovation[31]. - The company is actively pursuing the consistency evaluation of the quality and efficacy of its Benzalkonium Chloride Eye Drops as per regulatory requirements[11]. Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[31].

Financial Performance - The company achieved operating revenue of CNY 629.76 million in 2021, a year-on-year increase of 75.80% compared to CNY 358.23 million in 2020[22]. - The net profit attributable to shareholders was CNY 35.66 million in 2021, recovering from a loss of CNY 179.37 million in 2020[22]. - The cash flow from operating activities reached CNY 100.78 million, representing a 128.58% increase from CNY 44.09 million in 2020[22]. - The company reported a basic earnings per share of CNY 0.11 in 2021, compared to a loss of CNY 0.56 per share in 2020[23]. - The total assets decreased by 5.23% to CNY 1.59 billion at the end of 2021 from CNY 1.67 billion at the end of 2020[22]. - The company completed the acquisition of Taizhou Hospital in October 2020, contributing CNY 163 million in revenue for the full year of 2021[22]. - The weighted average return on equity increased to 2.68% in 2021, up by 15.51 percentage points from -12.83% in 2020[23]. - The company turned a profit in 2021, reporting a net profit attributable to shareholders of CNY 35.66 million, primarily due to reduced asset impairment provisions and stable operations at the acquired Taizhou Hospital, which contributed CNY 36.22 million in profit[50]. Research and Development - The company’s R&D expenses increased significantly, impacting profit contributions from its pharmaceutical manufacturing segment[22]. - R&D expenditure reached 102.21 million yuan, a year-on-year increase of 267.66%, accounting for 16.23% of operating revenue[31]. - The company has 71 R&D personnel, representing 5% of the total workforce[69]. - The company has initiated the development of multiple new products in 2021, significantly increasing R&D investment[70]. - The company is currently conducting preclinical research on a new generation of anti-cataract drugs, classified as a new drug of category 1.1[97]. - The company’s R&D investment capitalized ratio is 0%, indicating that all R&D expenditures were expensed in the current period[108]. - The company’s R&D investment compared to industry peers shows a significant commitment to innovation, with the average R&D investment in the industry being CNY 16.32 million[108]. Market and Competition - The pharmaceutical manufacturing industry is experiencing intensified competition and structural adjustments, driven by government policies promoting quality and cost efficiency[37]. - The company acknowledges the competitive landscape in the healthcare sector, particularly against public hospitals, and is focused on maintaining its brand and service quality[140]. - The company is actively engaging in the consistency evaluation of generic drugs to meet procurement requirements and enhance product competitiveness[86]. - The implementation of centralized drug procurement policies is expected to impact sales of non-winning products, although the direct effect on the company is currently minimal[85]. Corporate Governance and Compliance - The company has established a comprehensive internal control system to ensure compliance with governance standards and protect shareholder interests[145]. - The company has not reported any incidents of insider trading or regulatory penalties related to insider information management during the reporting period[146]. - The company has committed to transparency and accountability in its operations, accepting oversight from regulatory bodies and the public[200]. - The company has established a long-term commitment to uphold its promises and responsibilities to investors and stakeholders[200]. Social Responsibility and Environmental Management - The company has actively engaged in social responsibility initiatives, including a donation of 3 million yuan for disaster relief efforts[36]. - The company has established a public welfare fund and has conducted various community support activities, including eye disease prevention campaigns[196]. - The company was listed as a key pollutant discharge unit in Jiaxing City for 2021, with major pollutants including chemical oxygen demand and ammonia nitrogen[187]. - The company has implemented an emergency response plan for environmental incidents, filed with the local environmental protection bureau[192]. Future Outlook and Strategic Plans - The company expects to achieve operating revenue of 705 million yuan and a net profit of 56.99 million yuan in 2022[127]. - The company aims to improve operational efficiency and expand its medical service scale in response to the government's encouragement of private healthcare initiatives[88]. - The company plans to continue optimizing its product structure and expanding its market presence through strategic acquisitions and partnerships[53]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a focus on biotech firms[158].

Financial Performance - The company's operating revenue for Q3 2021 was ¥156,368,821.41, representing a year-on-year increase of 52.37%[3] - The net profit attributable to shareholders for the same period was ¥9,191,599.10, with a year-to-date net profit of ¥36,146,960.68[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥10,335,319.00, with a year-to-date figure of ¥35,641,147.21[3] - The basic earnings per share for Q3 2021 was ¥0.03, with a year-to-date figure of ¥0.11[3] - The net profit for the third quarter of 2021 was CNY 36,146,960.68, a significant recovery from a net loss of CNY 28,056,470.86 in the same period of 2020, marking a turnaround of over 228%[23] - Operating profit for the third quarter was CNY 47,093,345.56, compared to an operating loss of CNY 53,040,421.59 in the previous year, indicating a positive shift in operational performance[23] Revenue Growth - The company attributed the revenue growth to the addition of new medical segment businesses and increased sales of eye drops and cephalosporins[7] - The year-to-date operating revenue increased by 96.97% compared to the same period last year, driven by similar factors[7] - Total operating revenue for the first three quarters of 2021 reached ¥473,106,190.73, a significant increase from ¥240,193,945.35 in the same period of 2020, representing a growth of approximately 96.7%[22] - Total revenue from sales of goods and services received in the first three quarters of 2021 reached CNY 494,360,195.78, compared to CNY 269,193,229.97 in the previous year, reflecting an increase of about 83.6%[26] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was ¥42,341,400.32, showing an increase of 84.41%[3] - Cash flow from operating activities for the first three quarters of 2021 was CNY 42,341,400.32, up from CNY 22,959,883.89 in the same period of 2020, representing an increase of approximately 84%[26] - The cash and cash equivalents at the end of the reporting period stood at CNY 151,671,066.56, down from CNY 382,446,373.65 at the end of the previous year, indicating a decrease of approximately 60.3%[27] - The company recorded a net cash inflow from investing activities of CNY 2,549,093.06, a significant drop from CNY 139,545,699.76 in the previous year, showing a decrease of about 98.2%[27] - The total cash outflow from operating activities was CNY 483,508,952.38, compared to CNY 259,789,659.17 in the previous year, reflecting an increase of approximately 86.4%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,507,964,709.88, a decrease of 9.86% compared to the end of the previous year[4] - As of September 30, 2021, total assets amounted to ¥1,507,964,709.88, down from ¥1,672,903,308.03 at the end of 2020, a decrease of about 9.8%[19] - The total liabilities reached CNY 370.48 million, with current liabilities at CNY 361.92 million and non-current liabilities at CNY 8.57 million[32] - Current liabilities decreased significantly to ¥161,201,238.65 from ¥361,918,221.00, a reduction of approximately 55.5%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,921[9] - The largest shareholder, Chen Dekang, holds 52,572,504 shares, representing 16.30% of the total shares[9] - The total equity attributable to shareholders rose to ¥1,342,265,524.90 from ¥1,306,118,564.22, an increase of about 2.8%[19] Research and Development - Research and development expenses surged to ¥80,225,354.08 in the first three quarters of 2021, up from ¥14,659,276.24 in 2020, reflecting an increase of approximately 447.5%[22] - The company is focusing on market expansion and new product development, as indicated by the significant increase in R&D expenses[22] - The company has initiated a consistency evaluation for the benzalkonium chloride eye drops, with clinical trials currently underway[10] - The company has completed the recruitment of participants for the clinical trial of benzalkonium chloride eye drops and aims to expedite the process[10] Investment and Financial Management - The company plans to use up to 500 million RMB of idle funds for entrusted wealth management, which is 33.58% of the audited net assets as of December 31, 2019[11] - The company has committed to investing in low-risk, short-term financial products through entrusted wealth management[12] - The company has not reported any overdue principal or interest from its entrusted wealth management activities[12] Equity Transfer and Subsidiary Sale - The company adjusted the listing price for the 100% equity transfer of Qiangshen Pharmaceutical to 82 million RMB[14] - As of September 30, 2021, the company received 41.82 million RMB as the first payment for the equity transfer from Yue's Pharmaceutical[15] - The company has been actively pursuing the sale of its subsidiary, Qiangshen Pharmaceutical, with the process ongoing[13]